T细胞淋巴瘤研究新进展2014年国际T细胞淋巴瘤临床治疗大会报道.docx

自垒瘟：鲞里堡垫!堡生!!旦釜垫鲞笙!!塑』!!里堂!!堡!!!婴堕鱼坠墅也!婴塾堕竺!生竺垫!尘!!!：垫!堕!：!! ·641··国际进展速递·T细胞淋巴瘤研究新进展：20 1 4年国际T细胞淋巴瘤临床治疗大会报道马军 朱军石远凯姜文奇黄慧强邱林【摘要】 2014年国际T细胞淋巴瘤临床大会主要报告了T细胞淋巴瘤的治疗状况及进展，其中包 括靶向表观遗传学在T细胞淋巴瘤中的应用。有研究发现在外周T细胞淋巴瘤(PTCL)中控制DNA和 组蛋白甲基化的基因存在突变。根据这一研究结果应用组蛋白去乙酰化酶(HDAC)抑制剂belinostat和 romidepsin可使PTCL获得29％一38％的总反应率，中位缓解时间为13．6个月。NK／T细胞淋巴瘤是东 南亚国家常见的恶性淋巴瘤，在中国和日本占非霍奇金淋巴瘤的15％～28％，明显高于欧美国家，主要与亚洲人群EB病毒感染率高有关。应用含左旋门冬酰胺酶的方案如SMILE和AspMetDex方案，可使早 期病例长期生存率超过70％，晚期病例可达到近40％。对于PTCL可以将新药如普拉曲沙、罗眯酯肽等 联合应用，从而提高完全缓解率。【关键词】淋巴瘤，T细胞；表观遗传学；组蛋白；去乙酰化酶抑制剂Research progress of T ceH lymphoma： reports from 2014 international conference Oil T celllymphoma in clinical treatment Ma Jun4，Zhu Jun，Shi Yuankai，Jiang Wenqi，Huang Huiqiang,Qiu Lin．4Harbin Institute of HematologyOncology,Harbin 150010,ChinaCorrespoding author：Ma．tun，Email：majun0322@126．com【Abstract】The treatment status and progress in T cell lymphoma including epigenetic involved mutations that control DNA and histone methylation were reported and intensively discussed in 2014 international T cell lymphoma forum．According to the theory，treatment with HDAC inhibitor belinostat and romidepsin for peripheral T cell lymphoma(PTCL)can achieve 29％-38％overall response rate(ORR)and1 3．6 months median relief time．NIOT cell lymphoma in southeast asia is a common malignant lymphoma，15％-28％of the NHL accounted in China and Japan for．which is significantly higher than that in the European and American countries，mainly related to EB virus widespread infection．L-asparaginase enzymes， such as SMILE and AspMetDex．can make the early cases with more than 70％long-term survival rate． advanced cases with 40％response rate．Some new drugs．such as pralatrexate．combined with romidepsin can be used in PTCL cases to improve the complete remission rate．【Key words】Lymphoma，T cell；Epigenetic；Histone；Deacetylase inhibitor日前，由国际淋巴瘤联盟和中国抗淋巴瘤联盟主办的国际的报告题目为“对欧洲药品管理局(EMA)的挑战：外周T细 T细胞淋巴瘤临床治疗大会首次在中国厦门召开，由孙燕院 胞淋巴瘤药物如何给予优先权?”。外周T细胞淋巴瘤(PTCL) 士、管忠震教授、沈志祥教授、马军